Treatment of Ocular Inflammatory Disorders with Adalimumab: A Retrospective Case Series

  • Ahmed M. Bawazeer King Abdulaziz University
Keywords: Adalimumab, Ocular inflammatory disroders, Uveitis, Scleritis, Behcet's disease

Abstract

To determine the efficacy and safety of adalimumab in the treatment of ocular inflammatory disorders the records of five patients with sight-threatening ocular inflammatory disorders resistant to other immunosuppressive agents treated with Adalimumab 20-40 mg every two weeks were analyzed. A total of 5 patients: two patients had Behcet's disease; 1 had juvenile idiopathic arthritis-associated uveitis, 1 had anterior uveitis secondary to ankylosing spondylitis, and 1 had Idiopathic nodular scleritis. Five patients were treated (eight eyes examined) with Adalimumab; 4 males and 1 female, ranging in ages 9 to 52 years (mean: 27-years-old). All patients except patient 4 and 5 showed marked improvement in signs of ocular inflammation within 4 weeks from onset of therapy. However, patients’ No. 4 and 5 showed complete improvement in signs of ocular inflammation within 6 and 12 weeks, respectively.

Author Biography

Ahmed M. Bawazeer, King Abdulaziz University

Department of Ophthalmology

Published
2008-07-01
How to Cite
Bawazeer, A. M. (2008). Treatment of Ocular Inflammatory Disorders with Adalimumab: A Retrospective Case Series. Journal of King Abdulaziz University - Medical Sciences, 15(3), 39-51. https://doi.org/10.4197/med.15-3.3
Section
Articles